<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="MERSâ€�CoV. It is now being investigated as a potential candidate" exact="treatment" post="for SARSâ€�CoVâ€�2 having been identified as a candidate therapeutic"/>
 <result pre="properties, and is now being investigated as a potential candidate" exact="treatment" post="for viruses including SARSâ€�CoVâ€�2, which causes coronavirusâ€�19 disease (COVIDâ€�19)."/>
 <result pre="causes coronavirusâ€�19 disease (COVIDâ€�19). It has been used as a" exact="treatment" post="in previous coronavirus diseases during the epidemics of severe"/>
 <result pre="availability make it an attractive candidate for repurposing as a" exact="treatment" post="for COVIDâ€�19. Given the expected massive global impact of"/>
 <result pre="RV. AZM reduces RV replication and release during in vitro" exact="infection" post="of primary human bronchial epithelial cells (PBEC).7 This finding"/>
 <result pre="from patients with cystic fibrosis or healthy controls, where AZM" exact="treatment" post="again led to a sevenfold to ninefold reduction in"/>
 <result pre="rhinovirus (RV).35 Other macrolides also have antiâ€�viral effects in RV" exact="infection" post="including Mac5, an oleandomycin macrolide. Both AZM and Mac5"/>
 <result pre="viral protein expression in H1N1 influenza.45 In a shortâ€�term H1N1" exact="infection" post="model, AZM reduced expression of viral proteins 2â€‰days post"/>
 <result pre="further in vitro study found AZM to effectively suppress Zika" exact="infection" post="by targeting a late stage in the viral life"/>
 <result pre="spiramycin (another macrolide) provided significant in vivo protection against EVâ€�A71" exact="infection" post="in mice.13 Spiramycin impaired EVâ€�A71 viral RNA synthesis, and"/>
 <result pre="observational study, in which it was unknown on what basis" exact="treatment" post="allocation decisions were made, and randomised data are needed."/>
 <result pre="Betacoronavirus viral load, though there was no difference in the" exact="prevalence" post="of these viruses.10 Since the outbreak of the current"/>
 <result pre="AZM was also identified as a target in a bioinformatic" exact="screening" post="analysis of potentially relevant pathways with the potential for"/>
 <result pre="12LiC, ZuS, DengYQ, et al. Azithromycin protects against Zika virus" exact="infection" post="by upregulating virusâ€�induced type I and III interferon responses."/>
 <result pre="16LeeN, WongCK, ChanMCW, et al. Antiâ€�inflammatory effects of adjunctive macrolide" exact="treatment" post="in adults hospitalized with influenza: a randomized controlled trial."/>
 <result pre="ToKKW, JFWC, et al. Efficacy of clarithromycinâ€�naproxenâ€�oseltamivir combination in the" exact="treatment" post="of patients hospitalized for influenza a(H3N2) infection: an openâ€�label"/>
 <result pre="IIb/III trial. Chest. 2017;151(5):1069â€�1080.27884765 19HigashiF, KuboH, YasudaH, NukiwaT, YamayaM. Additional" exact="treatment" post="with clarithromycin reduces fever duration in patients with influenza."/>
 <result pre="lung injury. Chest. 2012;141(5):1153â€�1159.22116799 21TahanF, OzcanA, KocN. Clarithromycin in the" exact="treatment" post="of RSV bronchiolitis: a doubleâ€�blind, randomised, placeboâ€�controlled trial. Eur"/>
 <result pre="J. 2006;20(12):2121â€�2123.16914605 36JangYJ, KwonHJ, LeeBJ. Effect of clarithromycin on rhinovirusâ€�16" exact="infection" post="in A549 cells. Eur Respir J. 2006;27(1):12â€�19.16387930 37StroherU, DiCaroA,"/>
 <result pre="bioRxiv. 2020. 39SuzukiT, YamayaM, SekizawaK, et al. Erythromycin inhibits rhinovirus" exact="infection" post="in cultured human tracheal epithelial cells. Am J Respir"/>
 <result pre="2002;165(8):1113â€�1118.11956054 40SuzukiT, YamayaM, SekizawaK, et al. Bafilomycin A(1) inhibits rhinovirus" exact="infection" post="in human airway epithelium: effects on endosome and ICAMâ€�1."/>
 <result pre="HatachiY, et al. Clarithromycin inhibits type a seasonal influenza virus" exact="infection" post="in human airway epithelial cells. J Pharmacol Exp Ther."/>
 <result pre="al. Azithromycin, a 15â€�membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus" exact="infection" post="by interfering with virus internalization process. J Antibiot (Tokyo)."/>
 <result pre="Leucomycin A3, a 16â€�membered macrolide antibiotic, inhibits influenza A virus" exact="infection" post="and disease progression. J Antibiot (Tokyo). 2014;67(3):213â€�222.24496145 46FageC, PizzornoA,"/>
 <result pre="Microbiol. 2016;14(8):523â€�534.27344959 49BeigelJH, TomashekKM, DoddLE, et al. Remdesivir for the" exact="treatment" post="of Covidâ€�19â€&quot;preliminary report. N Engl J Med. 2020;NEJMoa2007764. doi:10.1056/NEJMoa2007764."/>
 <result pre="Invest. 2011;121(9):3554â€�3563.21804191 53AndreaniJ, Le BideauM, DuflotI, et al. In vitro" exact="testing" post="of combined hydroxychloroquine and azithromycin on SARSâ€�CoVâ€�2 shows synergistic"/>
 <result pre="54GautretP, LagierJ, ParolaP, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVIDâ€�19: results of an openâ€�label nonâ€�randomized clincial trial."/>
 <result pre="of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients" exact="testing" post="positive for coronavirus disease 2019 (COVIDâ€�19). JAMA Cardiol. 2020;e201834."/>
 <result pre="doi:10.1001/jamacardio.2020.1834. 56MaisonnasseP, GuedjJ, ContrerasV, et al. Hydroxychloroquine use against SARSâ€�CoVâ€�2" exact="infection" post="in nonâ€�human primates. Nature. 2020doi:10.1038/s41586-020-2558-4. 57BuonaguroFM, AsciertoPA, MorseGD, et"/>
 <result pre="J Surg Res. 2000;90(1):76â€�81.10781378 67SrivastavaP, VardhanH, BhengrajAR, et al. Azithromycin" exact="treatment" post="modulates the extracellular signalâ€�regulated kinase mediated pathway and inhibits"/>
 <result pre="Antimicrob Agents Chemother. 2004;48(9):3457â€�3461.15328111 105RibeiroCM, HurdH, WuY, et al. Azithromycin" exact="treatment" post="alters gene expression in inflammatory, lipid metabolism, and cell"/>
 <result pre="CervinA. A doubleâ€�blind, randomized, placeboâ€�controlled trial of macrolide in the" exact="treatment" post="of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189â€�193.16467702 108YamadaT, FujiedaS, MoriS, YamamotoH,"/>
 <result pre="chronic rhinosinusitis. Laryngoscope. 2006;116(2):189â€�193.16467702 108YamadaT, FujiedaS, MoriS, YamamotoH, SaitoH. Macrolide" exact="treatment" post="decreased the size of nasal polyps and ILâ€�8 levels"/>
 <result pre="136YanagiharaK, IzumikawaK, HigaF, et al. Efficacy of azithromycin in the" exact="treatment" post="of communityâ€�acquired pneumonia, including patients with macrolideâ€�resistant Streptococcus pneumoniae"/>
 <result pre="Med. 2009;48(7):527â€�535.19336954 137JakobssonHE, JernbergC, AnderssonAF, Sjolundâ€�KarlssonM, JanssonJK, EngstrandL. Shortâ€�term antibiotic" exact="treatment" post="has differing longâ€�term impacts on the human throat and"/>
</results>
